(Q44563272)

4 December 2017

title

Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes (English)

1 reference

4 December 2017

1 reference

1 reference

1 reference

Harte AL

1

1 reference

4 December 2017

McTernan PG

2

1 reference

4 December 2017

McTernan CL

3

1 reference

4 December 2017

Smith SA

4

1 reference

4 December 2017

Barnett AH

5

1 reference

4 December 2017

Kumar S

6

1 reference

4 December 2017

publication date

1 September 2003

1 reference

Diabetes, Obesity and Metabolism

4 December 2017

published in

1 reference

4 December 2017

volume

5

1 reference

4 December 2017

issue

5

1 reference

4 December 2017

page(s)

302-310

1 reference

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00276.X

Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00276.X

Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00276.X

Release of PAI-1 by human preadipocytes and adipocytes independent of insulin and IGF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00276.X

Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00276.X

Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00276.X

Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00276.X

Site-specific regulation of oestrogen receptor-alpha and -beta by oestradiol in human adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00276.X

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00276.X

Increased endothelin-1 and decreased adrenomedullin gene expression in the stenotic tissue of congenital pelvi-ureteric junction obstruction in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00276.X

Regional differences in protein production by human adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00276.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00276.X

Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00276.X

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00276.X

Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00276.X

10.1046/J.1463-1326.2003.00276.X

21 January 2018

Identifiers

DOI

1 reference

4 December 2017

1 reference